Evidence map›Paper›PMID 17427022›Full record

ArticleWiener klinische Wochenschrift2007

Subtype and genotypic resistance analysis of HIV-1 infected patients in Austria.

Barbara Falkensammer, Martin Doerler, Harald H Kessler, Elisabeth Puchhammer-Stoeckl, Walter Parson, Christina Duftner, Manfred P Dierich, Heribert Stoiber

Abstract read
PubMed Publisher
In one paragraph

Article in Wiener klinische Wochenschrift, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Barbara FalkensammerDepartment of Hygiene, Microbiology and Social Medicine, Innsbruck Medical University, Innsbruck, Austria. barbara.falkensammer@i-med.ac.at
Martin Doerler
Harald H Kessler
Elisabeth Puchhammer-Stoeckl
Walter Parson
Christina Duftner
Manfred P Dierich
Heribert Stoiber

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnalysis of HIV-1 subtypes and genotypic resistance have been shown to be relevant for epidemiologic and therapeutic studies or for vaccine development. In Europe, the majority of HIV-1 isolates belong to subtype B. Due to migration an increasing incidence for additional subtypes and complex recombinant forms are expected. OBJECTIVES AND STUDY

designTo evaluate the prevalence of HIV-1 subtypes in Austria, 188 plasma samples of treatment experienced patients were investigated. For phylogenetic analysis protease and reverse transcriptase genes were amplified and sequenced. Subtypes were determined by comparing reference sequences. For genotypic resistance determination, the Resistance-Algorithm-Comparison from Stanford University was used.

resultsNon-B subtypes were found in 20.2% of all patients with a dominant prevalence (50%) in the Southern provinces of Austria. With 85% CRF01_AE and CRF02_AG are the predominant circulating recombinant forms in Austria. When resistance mutations were analyzed, 57.4% of all patients were susceptible to all three groups of antiretroviral drugs, whereas in 12.2% resistance against all three classes of antiretroviral drugs was found.

conclusionHIV-1 subtype B is still dominant in major parts of Austria. However, a significantly increasing percentage of non-B subtypes and recombinant forms are observed in the Southern provinces.

Indexed as

GenotypeAdultAntiviral AgentsDrug Resistance, ViralEmigration and ImmigrationFemaleHIV-1HIV InfectionsHIV ProteaseHIV Reverse TranscriptaseHumansMalePhylogenyPolymerase Chain ReactionRecombination, GeneticRetrospective StudiesAntiviral AgentsHIV ProteaseHIV Reverse Transcriptase

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.